Kadimastem hopes to turn corner with new management
The Israeli stem cell technology company has named Asaf Shiloni CEO, after three new expert directors joined its board.
Israeli stem cell technology company Kadimastem (TASE: KDST) has had a chequered history, with frequent going concern warnings on its financials, a downward drifting share price from its 2016 peak, and the departure last year of founder and CEO Yossi Ben-Yosef. The company now hopes to have turned a corner with the appointment of a new and experienced CEO and new directors.
Kadimastem has named Asaf Shiloni, who was Vice President of Sales and Business Development at California-based PeproTech Inc., as CEO. PeproTech is the leading manufacturer of GMP Cytokines, vital components in all stem cell and cell therapy clinical trials. Kadimastem s announcement states that at PeproTech Shiloni established collaborations and joint ventures with top US stem cell companies and leading research labs worldwide, and also led